Literature DB >> 2910416

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.

C L Carter1, C Allen, D E Henson.   

Abstract

Two of the most important prognostic indicators for breast cancer are tumor size and extent of axillary lymph node involvement. Data on 24,740 cases recorded in the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute were used to evaluate the breast cancer survival experience in a representative sample of women from the United States. Actuarial (life table) methods were used to investigate the 5-year relative survival rates in cases with known operative/pathologic axillary lymph node status and primary tumor diameter. Survival rates varied from 45.5% for tumor diameters equal to or greater than 5 cm with positive axillary nodes to 96.3% for tumors less than 2 cm and with no involved nodes. The relation between tumor size and lymph node status was investigated in detail. Tumor diameter and lymph node status were found to act as independent but additive prognostic indicators. As tumor size increased, survival decreased regardless of lymph node status; and as lymph node involvement increased, survival status also decreased regardless of tumor size. A linear relation was found between tumor diameter and the percent of cases with positive lymph node involvement. The results of our analyses suggest that disease progression to distant sites does not occur exclusively via the axillary lymph nodes, but rather that lymph node status serves as an indicator of the tumor's ability to spread.

Entities:  

Mesh:

Year:  1989        PMID: 2910416     DOI: 10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  443 in total

1.  Growth of Breast Cancer and Limited Surgery.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

Review 2.  Prognostic factors in breast cancer: current and new predictors of metastasis.

Authors:  D F Hayes; C Isaacs; V Stearns
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

Review 3.  AN OVERVIEW OF PROGNOSTIC MARKERS IN BREAST CANCER.

Authors:  G U Deshpande; Ramji Rai
Journal:  Med J Armed Forces India       Date:  2017-06-26

4.  Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Authors:  Vandana Gupta Abramson; Andrea B Troxel; Michael Feldman; Carolyn Mies; Yan Wang; Lauren Sherman; Sara McNally; Alan Diehl; Angela Demichele
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

Review 5.  Preoperative assessment of prognostic factors in breast cancer.

Authors:  H Denley; S E Pinder; C W Elston; A H Lee; I O Ellis
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

6.  Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

Authors:  Mevlude Inanc; Metin Ozkan; Halit Karaca; Veli Berk; Oktay Bozkurt; Ayse Ocak Duran; Ersin Ozaslan; Hulya Akgun; Fatos Tekelioglu; Ferhan Elmali
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

7.  Questioning the role of axillary node dissection in sentinel node positive early stage breast cancer in the South Eastern Cancer Centre.

Authors:  O O Mohamed; P M Neary; C Fiuza-Castineira; G T O'Donoghue
Journal:  Ir J Med Sci       Date:  2014-03-02       Impact factor: 1.568

8.  Inversion of displacement fields to quantify the magnetic particle distribution in homogeneous elastic media from magnetomotive ultrasound.

Authors:  Diwash Thapa; Benjamin E Levy; Daniel L Marks; Amy L Oldenburg
Journal:  Phys Med Biol       Date:  2019-06-20       Impact factor: 3.609

9.  Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma.

Authors:  Jayasri G Iyer; Barry E Storer; Kelly G Paulson; Bianca Lemos; Jerri Linn Phillips; Christopher K Bichakjian; Nathalie Zeitouni; Jeffrey E Gershenwald; Vernon Sondak; Clark C Otley; Siegrid S Yu; Timothy M Johnson; Nanette J Liegeois; David Byrd; Arthur Sober; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2014-02-09       Impact factor: 11.527

10.  Personalized medicine in breast cancer: a systematic review.

Authors:  Sang-Hoon Cho; Jongsu Jeon; Seung Il Kim
Journal:  J Breast Cancer       Date:  2012-09-28       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.